ACC 2019 | TAVR in Bicuspids is Safe and Feasible in Real World Patients

Experts still won’t agree on whether to carry out randomized trial to put an end to this discussion, but it seems clear that balloon expandable TAVR is valid only for certain anatomies.  

ACC 2019 | TAVI en bicúspides es seguro y factible en pacientes seleccionados del mundo realTAVR in real world bicuspid valve populations is associated with similar outcomes at 30 days and one year when compared against cohorts with regular valves, according to the new registry.

 

However, patients with bicuspid anatomy have higher risk of root rupture, conversion to conventional surgery, and stroke.

 

Data have given grounds for TAVR to be considered a reasonable alternative for patients at high or intermediate risk of surgery, which calls for a randomized study.


Read also: ACC 2019 | PARTNER 3: Low Risk TAVR vs. Surgery, Fewer Events per Year.


This registry shows that patients with bicuspid anatomy required more conversion to surgery (0.9% vs 0.4%; p=0.03) and presented more annulus rupture (0.3% vs 0; p=0.02). Numerically, yet not significantly, a second valve was needed for bicuspid patients.

 

At 30 days, there were no differences in all-cause mortality, life threatening bleeding, vascular complications or reinterventions in both groups. The difference lies on a higher stroke rate in the bicuspid cohort (2.4% vs 1.6%; p=0.02) and the need for pacemaker implantation (9.1% vs 7.5%; p=0.03). Most strokes were periprocedural.

 

At one year, these differences disappeared both in mortality and in stroke, and also in the combination of both events.


Read also: ACC 2019 | TAVR in Low-Risk Patients Is Noninferior.


Paravalvular leak tended to be higher in bicuspid patients (p=0.08) but resulted equivalent at 30 days and one year, compared with the tricuspid cohort.  

 

Original title: Outcomes of transcatheter aortic valve replacement with balloon-expandable Sapien 3 valve in bicuspid aortic stenosis: an analysis of the STS/ACC TVT registry.

Presenter: Makkar RR.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...